ABVC Biopharma Stock Price Gains 20% as Lucidam Deal Hits the Market

Practice Stock Trading Your Capital Is At Risk
Nigel Frith
Updated: 15 Oct 2021

The stock price of ABVC Biopharma (NASDAQ: ABVC) made further gains in Friday trading, extending weekly gains by a further 20%. The clinal-stage biopharmaceutical company recently announced an exciting venture agreement with Tokyo-based Lucidam, a private investment firm.

new-recommended-broker-banner

The news has had a trickle effect on the market, with a slight delay on the expected bull rush, seeing gains increase dramatically 2-3 days after the initial news release. Whether investors were skeptical, cautious, or just late to the party, it’s a different story in premarket trading today – the venture deal is starting to fuel the fires of ABVC, currently holding gains of just under 20%. 

Details of the agreement include calls for business development collaboration through Lucidam affiliate BioLite Japan. BioLite will aim to identify early-stage opportunities in the drug development space as well as digital health and technological innovation in medical devices. 

As far as ownership is concerned, ABVC will maintain equity ownership of BioLite Japan at 49%, with Lucidam holding the other 51%. 

It isn’t that surprising that investors took to this deal with vigor, regardless of a slight delay. The partnership has the potential to drive innovation in this space, whilst creating a cohesive corporate frame that serves ABVC’S best interests. 

CEO of ABVC, Dr. Howard Doong speaks on the fruitful potential of the partnership:

“This joint venture should allow us to further ensure access to additional early-stage product candidates that we otherwise would not have access to without this partnership. Dr. Seo has a distinguished career in healthcare and business in Japan and Asia and will play a significant role in expanding our pipeline at an accelerated pace.”

The ABVC Pharma stock price is pushing the $3 mark entering into Friday’s market open, recoding gains of over 25%.

Should You Invest in ABVC Pharma Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .